clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Lung Diseases, Obstructive D008173 10 associated lipids
Lung Diseases D008171 37 associated lipids
Leprosy D007918 8 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Klebsiella Infections D007710 7 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Ischemia D007511 18 associated lipids
Iritis D007500 2 associated lipids
Iris Diseases D007499 2 associated lipids
Insulin Resistance D007333 99 associated lipids
Influenza, Human D007251 11 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Hypoproteinemia D007019 1 associated lipids
Hyperlipidemias D006949 73 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Hypercholesterolemia D006937 91 associated lipids
HIV Seropositivity D006679 15 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Fan W et al. An unusual case of folliculitis spinulosa decalvans. 2016 Cutis pmid:27814407
Miftahussurur M et al. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. 2016 BMC Microbiol. pmid:27809767
Phaw NA and Tsai HH Eosinophilic gastroenteritis: a challenge to diagnose and treat. 2016 BMJ Case Rep pmid:27613263
Plate A [Not Available]. 2016 Praxis (Bern 1994) pmid:27606919
Huh CW et al. Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates. 2016 PLoS ONE pmid:27588679
Watanabe M et al. Saturated fatty acids and fatty acid esters promote the polymorphic transition of clarithromycin metastable form I crystal. 2016 Int J Pharm pmid:27553780
Khonche A et al. Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial. 2016 Drug Res (Stuttg) pmid:27351245
Büchsel M et al. A case of septic arthritis caused by a Mycoplasma salivarium strain resistant towards Ciprofloxacin and Clarithromycin in a patient with chronic lymphatic leukemia. 2016 Diagn. Microbiol. Infect. Dis. pmid:27342785
Lin LC et al. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. 2016 World J. Gastroenterol. pmid:27340362
Wong AY et al. Association Between Acute Neuropsychiatric Events and Helicobacter pylori Therapy Containing Clarithromycin. 2016 JAMA Intern Med pmid:27136661
Zollner-Schwetz I et al. Primary resistance of Helicobacter pylori is still low in Southern Austria. 2016 Int. J. Med. Microbiol. pmid:27134190
Georgopoulos SD et al. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. 2016 Eur. J. Intern. Med. pmid:27134145
Blake Z Study provides insufficient evidence of a link between clarithromycin and myocardial infarction. 2016 BMJ pmid:26955978
Seyama S et al. Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan. 2016 Antimicrob. Agents Chemother. pmid:26953210
Ji Z et al. The Association of Age and Antibiotic Resistance of Helicobacter Pylori: A Study in Jiaxing City, Zhejiang Province, China. 2016 Medicine (Baltimore) pmid:26937912
Murakami K et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. 2016 Gut pmid:26935876
Kefeli A et al. Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial. 2016 Bosn J Basic Med Sci pmid:26773183
Iyer G and Alexander GC Cardiovascular risks associated with clarithromycin. 2016 BMJ pmid:26769796
Wong AY et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. 2016 BMJ pmid:26768836
Djennane-Hadibi F et al. High-Level Primary Clarithromycin Resistance of Helicobacter pylori in Algiers, Algeria: A Prospective Multicenter Molecular Study. 2016 Microb. Drug Resist. pmid:26554340
Siddiqui TR et al. Emerging trends of antimicrobial resistance in Helicobacter pylori isolates obtained from Pakistani patients: The need for consideration of amoxicillin and clarithromycin. 2016 J Pak Med Assoc pmid:27339574
Lee J et al. A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM. 2016 J. Matern. Fetal. Neonatal. Med. pmid:26441216
Apostolopoulos P et al. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. 2016 Scand. J. Gastroenterol. pmid:26435055
Shallom SJ et al. New Real-Time PCR Assays for Detection of Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Group. 2015 J. Clin. Microbiol. pmid:26269619
Zagari RM et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. 2015 Dig Liver Dis pmid:26253555
Sprague J et al. Cutaneous infection with Mycobacterium kansasii in a patient with myelodysplastic syndrome and Sweet syndrome. 2015 Cutis pmid:26244358
Sharara AI et al. Letter: clarithromycin dose for H. pylori therapy remains unresolved--authors' reply. 2015 Aliment. Pharmacol. Ther. pmid:26238584
Graham DY and Gisbert JP Letter: clarithromycin dose for H. pylori therapy remains unresolved. 2015 Aliment. Pharmacol. Ther. pmid:26238583
Kasai A et al. Prevalence and molecular analysis of macrolide-resistant Moraxella catarrhalis clinical isolates in Japan, following emergence of the highly macrolide-resistant strain NSH1 in 2011. 2015 J. Med. Microbiol. pmid:25934551
Chou HW et al. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study. 2015 Clin. Infect. Dis. pmid:25409476
Flores-Gonzalez JC et al. [Etiology, clinical presentation and outcome of severe viral acute childhood encephalitis (ECOVE study)]. 2015 Rev Neurol pmid:26108903
Hill FJ et al. From a fish tank injury to hospital haemodialysis: the serious consequences of drug interactions. 2015 BMJ Case Rep pmid:26106178
Ito A et al. Increase in SCCmec type IV strains affects trends in antibiograms of meticillin-resistant Staphylococcus aureus at a tertiary-care hospital. 2015 J. Med. Microbiol. pmid:25934550
AktaÅŸ B et al. The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies. 2015 Eur J Gastroenterol Hepatol pmid:25919773
Bouilhat N et al. High-level primary clarithromycin resistance of Helicobacter pylori in Morocco: a prospective multicenter molecular study. 2015 Helicobacter pmid:25735573
Guzman Vinasco L et al. Acute suppurative parotitis caused by Streptococcus pneumoniae in an HIV-infected man. 2015 BMJ Case Rep pmid:25733094
Mitsui Y et al. Gastric inflammatory fibroid polyp morphologically changed by Helicobacter pylori eradication. 2015 Clin J Gastroenterol pmid:25733031
Ben Chaabane N and Al-Adhba HS Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial. 2015 Indian J Gastroenterol pmid:25721770
Townsell MY et al. Pathology in practice. Canine distemper virus disease in a dog. 2015 J. Am. Vet. Med. Assoc. pmid:25719842
Brown-Elliott BA et al. Absence of a functional erm gene in isolates of Mycobacterium immunogenum and the Mycobacterium mucogenicum group, based on in vitro clarithromycin susceptibility. 2015 J. Clin. Microbiol. pmid:25568437
Zhang L et al. [Minocycline quadruple versus tailored therapy in retreatment of Helicobacter pylori infection]. 2015 Zhonghua Nei Ke Za Zhi pmid:26887366
Alimadadi M et al. Impact of creatinine clearance on Helicobacter pylori eradication rate in patients with peptic ulcer disease. 2015 Iran J Kidney Dis pmid:26552348
Karpiński TM et al. Evaluation of antimicrobial resistance of Helicobacter pylori in the last 15 years in West Poland. 2015 Acta Microbiol Immunol Hung pmid:26551571
John A et al. Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection? 2015 Indian J Gastroenterol pmid:26541342
Mel-Hennawi D and Ahmed MR Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion. 2015 J Laryngol Otol pmid:26521817
Parra D et al. In vitro efficacy of daptomycin and teicoplanin combined with ethanol, clarithromycin or gentamicin as catheter lock solutions. 2015 BMC Microbiol. pmid:26518881
Hwang JJ et al. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. 2015 World J. Gastroenterol. pmid:26401089
Weiss S et al. Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits. 2015 Antimicrob. Agents Chemother. pmid:26392505
Agrawal V et al. A Case of Hypotension and Bradycardia Precipitated by Drug Interaction of Clarithromycin and Calcium-Channel Blocker. 2015 J Am Geriatr Soc pmid:26389998
Hauser G et al. Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial. 2015 Medicine (Baltimore) pmid:25929897